Clinical Trials Directory

Trials / Completed

CompletedNCT02096211

Ceramic-on-Ceramic (COC) 36mm Acetabular Bearing Insert Post Approval Study-New Subjects (COC36mmPAS)

36mm CERAMAX® Ceramic Hip System PMA PAS STUDY: Short to Mid-Term Follow-up , New Study Subjects (Ceramic Hip System, Subjects Receive CERAMAX 36mm Ceramic Acetabular Bearing Insert That Articulates With a Ceramic Femoral Head for THA)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
172 (actual)
Sponsor
DePuy Orthopaedics · Industry
Sex
All
Age
21 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study is intended to gather short (Pre-operative to 4-years) and mid-term (5-years) information regarding the performance and safety of the commercially available 36mm CERAMAX® Ceramic on Ceramic Total Hip System from a cohort of new study subjects that were not previously involved in the IDE study for this device.

Detailed description

Up to 10 (up to 5 original IDE + 5 new sites) A prospective, non-controlled, non-randomized, multicenter study. Subjects will be seen for a clinic visit pre-operatively at the time of consent, (-90 days to surgery) and then at post-operatively at 6 weeks (1-92 days), 1 year (275-455 days), 2 years (640-820 days) and 3 years (1005-1185days), 4 years (1370-1550 days), and a minimum of 5 years (1825- 2555 days). Data collected will include: Pre-operatively subject history and demographics; Operative and device details; and Post-operatively Harris HIp scores, Subject Hip Outcomes, and Adverse Events. In order to optimize mid-term follow-up compliance, site personnel are permitted to contact the study subject in the 3 and 4 year intervals by phone (in place of a clinic visit) to assess the current status of the hip.

Conditions

Interventions

TypeNameDescription
DEVICECOC 36mmTotal Hip Replacement with COC 36mm Acetabular Cup System

Timeline

Start date
2014-06-01
Primary completion
2023-12-31
Completion
2023-12-31
First posted
2014-03-26
Last updated
2025-07-16
Results posted
2025-05-06

Locations

13 sites across 2 countries: United States, Canada

Regulatory

Source: ClinicalTrials.gov record NCT02096211. Inclusion in this directory is not an endorsement.